

13 March 2019

ASX Code: MXC

European corporate and pharmaceutical industry expert Dr. Stephen Parker appointed Non-Executive Director

- Experienced European corporate, pharmaceutical industry and investment director, Dr. Stephen Parker has been appointed to the MXC Board as Non-Executive Director
- His appointment brings MXC 30+ years of experience, deep sector understanding and an extensive network of connections within the pharmaceutical and investment industries
- Dr Parker currently holds multiple prestigious Board positions at leading UK listed Biopharma companies, including Sareum Holdings plc and Silence Therapeutics plc.
- Dr Parker's appointment demonstrates MXC's commitment to developing and expanding its European operations and delivering on its seed-to-pharma growth strategy

MGC Pharmaceuticals Ltd (ASX: MXC, "MGC Pharma" or "the Company") is delighted to welcome Dr Stephen Parker to the Board as Non-Executive Director, effective 13 March 2019. Dr Parker brings highly complementary pharmaceutical industry and corporate expertise to the Board and will provide support for the implementation and execution of the Company's strategy to become a leading European bio-pharma company within the medicinal cannabis sector.

Dr Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focussed on the pharmaceutical and biotechnology sectors in the UK, Europe and North America. He is currently Non-Executive Chairman of AIM listed oncology therapeutics company, Sareum Holdings Plc (LON: SAR) and a Non-Executive Director of AIM-listed RNA-therapeutics focussed company, Silence Therapeutics Plc (LON: SLN).

Dr Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution. This has led to senior consulting roles at a number of listed companies, as well as his investment banking experience at Baring Brothers, SBC Warburg Dillon Read and Apax Partners. He is FCA authorised, an affiliate of the Institute of Chartered Accountants in England & Wales (ICAEW) and a Fellow of both the Royal Society of Chemistry and Royal Society of Medicine.

The Board believes that Dr Parker's extensive experience working with pharmaceutical and investment companies will be invaluable for MGC Pharma and its growth. His relationships strengthen the Company's market position within the UK and Europe and with both support the operational business and expedited access into the UK pharmaceutical capital market. Furthermore, his appointment reinforces the Company's commitment to delivering exclusively on its seed-to-pharma growth strategy from its existing EU base of operations, and the planned expansion of its MGC Pharma product pipeline starting with CannEpil and CogniCann, into key emerging European and UK medicinal cannabis markets. CannEpil is the Company's proprietary CBD-based medication that is used as a treatment for people with refractory epilepsy and CogniCann is being developed for the treatment of major dementia symptoms and improve certain cognitive functions.

Commenting on his appointment, Stephen Parker, Non- Executive Director said:

“MGC Pharma is a standout company within the medical cannabis space with a clear development path and excellent growth potential. I am delighted to join the already highly experienced research and operational team and I am looking forward to playing an active role in the development and expansion of the Company’s international presence. Having worked within the pharmaceutical investment world for many years I can clearly recognise the potential in the cannabinoid sector, and I believe the structure, operational platform and product pipeline of MGC Pharma will drive it to the forefront of the European industry.”

Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

“We are delighted to welcome Stephen to the Board of MGC Pharmaceuticals and look forward to working with him as we look to create and supply best in class Cannabinoid based pharmaceutical products for medical markets in Europe, North America and Australasia.”

“His experience in London with various investment banks and pioneering pharmaceutical companies has given Stephen a unique and focussed skill set which will be an asset to us. The sale of MGC Derma and Stephen’s appointment have coincided perfectly and facilitate the next stage of development as a biopharma company. I look forward to providing regular update as we progress the business and deliver on our strategy”

--End--

For further information, please contact:

Media Enquiries

Justin Kelly
Media and Capital Partners
+61 408 215 858
Justin.kelly@mcpartners.com.au

UK IR/Media Advisors

Gaby Jenner/ Catherine Leftley
St Brides Partners Ltd
+44 (0) 207 236 1177
gaby@stbridespartners.co.uk
catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   